UNSPSC 51283945: Sulfadiazine silver

This classification denotes a topical anti-infective agent and sulfonamide anti-infective agent with the molecular formula C10H9N4O2S.Ag, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W46JY43EJR, chemically known as sulfanilamide, n(sup 1)-2-pyrimidinyl-, monosilver(1+) salt but more generally known as silver sulfadiazine, which bears US NIH Compound Identifier 31011. European Medicines Agency schedules Silver sulfadiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04622MIG.

World Health Organization schedules silver sulfadiazine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule sulfadiazine silver under HS 29350090 and SITC 51580. SMILES: C1CNC(NC1)[N-]S(=O)(=O)C2CCC(CC2)N.[AG+].

UNSPSC 51283945 Sulfadiazine silver, a Commodity code, shows limited recent activity aligned with its nominal scope. State and local procurement records do not surface open solicitations or awarded contracts for sulfadiazine silver products during the reference period. The two most recent opportunities tagged to this code — an Illinois Department of Public Health pharmaceutical warehouse piggyback award for antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) and a Seminole County, Florida IFB for Naloxone and drug deactivation systems — are unrelated to topical burn-wound or antiseptic silver compounds and appear to reflect coding misclassifications in the source systems.

Without verifiable recent opportunities directly matching sulfadiazine silver procurement, no meaningful geographic concentration, issuing-body pattern, or market activity can be identified for this code at the state and local level. Firms evaluating this code should verify that procurement systems in target states and jurisdictions are tagging wound-care pharmaceuticals and antimicrobial agents correctly, or consider higher-tier UNSPSC families covering pharmaceutical supply more broadly to capture actual buying activity.